Home » Newsletters » BioWorld Science

BioWorld Science

May 10, 2022

View Archived Issues

Targeting NMNAT2 confers neuroprotection in glaucoma

Hangzhou Zhongmei Huadong Pharmaceutical divulges GLP-1 receptor agonists

Universite du Luxembourg discloses new PDE6D inhibitors

Ranok Therapeutics presents new CHAMPs for cancer

Beijing Jacobio Pharmaceuticals identifies new glutaminase inhibitors

Shanghai De Novo Pharmatech synthesizes new ATR kinase inhibitors

Discovery of potent and orally bioavailable CSNK1A1 inhibitors

Clec9A-M2e construct may be a step towards a universal influenza vaccine

ANGPTL7 as a novel therapeutic target for glaucoma

TBK1 inhibition is neuroprotective in optic neuropathies

iBio presents preclinical data on monoclonal antibody candidate IBIO-101 for solid tumors

Ichnos selects trispecific antibody ISB-2001 for development in multiple myeloma

Aqilion advances program for chronic inflammatory bowel disease

Researchers develop a murine model of TEK Schlemm's canal conditional knockdown glaucoma

Comparative study focuses lens of human reproductive aging

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026